- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Budesonide Formoterol Inhaler
Budesonide/formoterol combination inhaler (brand name Symbicort) is a fixed‑dose inhaled therapy containing the corticosteroid budesonide and the long‑acting beta₂‑agonist (LABA) formoterol fumarate dihydrate. It is indicated for the maintenance treatment of asthma in patients aged 12 years and older where an inhaled corticosteroid and a LABA are appropriate, and for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults with frequent exacerbations despite regular use of a long‑acting bronchodilator. Budesonide reduces airway inflammation, while formoterol provides rapid and prolonged bronchodilation by stimulating beta₂‑receptors in airway smooth muscle. In Canada, Symbicort may also be used as a single maintenance and reliever therapy (SMART) for moderate to severe asthma, where patients use the same inhaler for both daily maintenance and as‑needed relief of symptoms.
Usual adult dose: Dosing is individualized based on disease severity and product formulation. For the dry powder Turbuhaler, typical starting doses for asthma are 1 to 2 inhalations of the 100 mcg/6 mcg or 200 mcg/6 mcg strength twice daily; the maximum recommended maintenance dose is 4 inhalations of 200 mcg/6 mcg twice daily (total 1600 mcg budesonide per day). For COPD, the usual dose is 2 inhalations of 200 mcg/6 mcg twice daily. The 400 mcg/6 mcg strength is reserved for patients with severe disease. For the pressurized metered‑dose inhaler (pMDI), similar twice‑daily regimens apply with the 100 mcg/6 mcg, 160 mcg/4.5 mcg, and 200 mcg/6 mcg strengths. When used as SMART therapy, patients take a prescribed maintenance dose (e.g., 1 to 2 inhalations twice daily) plus an additional 1 inhalation as needed for symptom relief, up to a maximum total of 6 or 8 inhalations per day. The mouth should be rinsed with water and spit out after each maintenance dose to reduce the risk of oral thrush and hoarseness.
Dosage form: Available as a dry powder for oral inhalation (Turbuhaler) delivering 100 mcg/6 mcg, 200 mcg/6 mcg, or 400 mcg/6 mcg of budesonide/formoterol per actuation; and as a pressurized metered‑dose inhaler (pMDI) delivering 100 mcg/6 mcg, 160 mcg/4.5 mcg, or 200 mcg/6 mcg per actuation.
Onset of action: Formoterol produces bronchodilation within 1 to 3 minutes of inhalation, comparable to the speed of short‑acting rescue bronchodilators. The anti‑inflammatory effect of budesonide develops over days; significant asthma symptom control and lung function improvement are typically seen within 1 to 2 weeks of continuous therapy, with maximum benefit achieved after several weeks.
Duration of action: The bronchodilator effect of formoterol lasts for at least 12 hours, supporting twice‑daily maintenance dosing. The anti‑inflammatory activity of budesonide persists throughout the dosing interval, providing 24‑hour protection against airway inflammation when used regularly.
Alcohol recommendation: No direct interaction between inhaled budesonide/formoterol and alcohol is known. However, excessive alcohol consumption may worsen GERD, which can trigger or exacerbate asthma symptoms, and may potentially amplify systemic side effects of the corticosteroid component. Patients should drink in moderation.
Most common side effects: Oropharyngeal candidiasis (thrush), dysphonia (hoarseness), throat irritation, headache, tremor, palpitations, and muscle cramps. The risk of local fungal infections and voice changes is reduced by rinsing the mouth after each inhalation. Formoterol, as a LABA, may cause dose‑dependent tremor, tachycardia, and palpitations, which typically diminish with continued use. High‑dose or prolonged therapy with inhaled corticosteroids can lead to systemic effects including adrenal suppression, bone density loss, cataracts, and glaucoma; the lowest effective dose should be used. In SMART therapy, patients and caregivers must be carefully educated on the maximum allowable daily doses and on recognizing signs of worsening asthma. The product is not a rescue inhaler when used for maintenance‑only regimens; however, when prescribed as a SMART inhaler, it can be used for acute symptom relief. Paradoxical bronchospasm after inhalation is a rare but serious event requiring immediate discontinuation and medical evaluation. In COPD, pneumonia is a known risk associated with higher doses of inhaled corticosteroids.
Would you like to try Budesonide/Formoterol Inhaler without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
